Last reviewed · How we verify
NCT03358966
Energy Expenditure in Chronic Kidney Disease
trial testing Doubly-labelled water technique in Kidney Diseases in 80 participants. Completed in 30 May 2015.
30 May 2014
Quick facts
| Lead sponsor | East and North Hertfordshire NHS Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 80 |
| Start date | 1 September 2008 |
| Primary completion | 30 May 2014 |
| Estimated completion | 30 May 2015 |
Drugs / interventions tested
- Doubly-labelled water technique
- Resting Energy Expenditure
Conditions studied
- Kidney Diseases — all drugs for Kidney Diseases →
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Sponsor
East and North Hertfordshire NHS Trust
Who can join
18 and older, any sex, with Kidney Diseases or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with kidney disease need accurate advice on their diet. Researchers know very little about energy needs and nutritional requirements in kidney patients. Simple tools are needed to calculate calorie requirements so that good bed-side advice can be given to patients, and to allow cost-effective research. This study aimed to measur energy requirements in kidney disease using a gold-standard safe and very accurate method called the "doubly labelled water technique". The study has compared measurements with less costly measurements obtained using a device which measures oxygen content of air breathed out. The study has also measured physical activity levels with questionnaires.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03358966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Diseases
Currently open trials in the same condition.
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07217535 — Rutgers University Study of the Genetics of Kidney Disease · recruiting
- NCT06858319 — Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. · Phase 3 · recruiting
- NCT06798909 — Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients · Phase 3 · recruiting
- NCT06759077 — Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of Life · Phase 3 · active not recruiting
Other East and North Hertfordshire NHS Trust trials
Trials by the same sponsor.
- NCT07069998 — AI-guided AF Treatment · NA · not yet recruiting
- NCT06915909 — Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial · NA · not yet recruiting
- NCT06863090 — In Vivo Dosimetry for Brachytherapy Study · recruiting
- NCT06623123 — Oto Smartphone App in Treating Tinnitus Amongst Adult Patients Compared with Standard Talking Therapies · Phase 3 · recruiting
- NCT06400927 — Safety of AI-Powered Virtual Assistant in Outpatient Management of Heart Failure · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03358966 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by East and North Hertfordshire NHS Trust
- Last refreshed: 4 December 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03358966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing